Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Risperidone versus haloperidol: II. Cost-effectiveness.

Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I.

Clin Ther. 1998 Jan-Feb;20(1):196-213.

PMID:
9522115
2.

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

Chue PS, Heeg B, Buskens E, van Hout BA.

Pharmacoeconomics. 2005;23 Suppl 1:62-74.

PMID:
16416762
3.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
4.

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.

Pharmacoeconomics. 2005;23(3):299-314.

PMID:
15836010
5.

Impact of newer antipsychotics on outcomes in schizophrenia.

Keks NA.

Clin Ther. 1997 Jan-Feb;19(1):148-58; discussion 126-7.

PMID:
9083717
6.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
7.

A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.

Glazer WM, Ereshefsky L.

J Clin Psychiatry. 1996 Aug;57(8):337-45.

PMID:
8752015
8.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
9.
10.

Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Foster RH, Goa KL.

Pharmacoeconomics. 1998 Jul;14(1):97-133. Review.

PMID:
10182198
11.
12.

Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.

Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA.

J Clin Psychiatry. 1999 Dec;60(12):850-6.

PMID:
10665632
13.
14.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.

Pharmacoeconomics. 2005;23 Suppl 1:35-47.

PMID:
16416760
15.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

16.

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.

Heeg BM, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout BA.

Curr Med Res Opin. 2008 Feb;24(2):349-58.

PMID:
18081988
17.

Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.

Oh PI, Iskedjian M, Addis A, Lanctôt K, Einarson TR.

Can J Clin Pharmacol. 2001 Winter;8(4):199-206.

PMID:
11743592
18.

Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.

Obradovic M, Mrhar A, Kos M.

Int J Clin Pract. 2007 Dec;61(12):1979-88. Review.

PMID:
17997804
19.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
20.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124

Supplemental Content

Support Center